Pulmonary Arterial Hypertension: Best Practice for Diagnosis and Management
Pulmonary hypertension (PH) is a progressive disease that continues to have poor 5-year survival rates. Pulmonary arterial hypertension (PAH) is one of 5 subtypes of PH. Because PAH is rare and the signs and symptoms nonspecific, clinicians often do not consider it in the differential diagnosis. When the diagnosis is considered, patients may not undergo all required testing for diagnostic accuracy and for many the diagnosis is delayed 3 or 4 years.
Determination of risk is key to selecting the appropriate therapy for patients with PAH, and evidence-based guidance for establishing level of risk has been published. Clinicians have several classes of agents to choose from when developing a management strategy for PAH. The patient’s experience and treatment goals should also be considered. "Pulmonary Arterial Hypertension: Best Practice for Diagnosis and Management" will provide clinicians with information about diagnostic criteria and evidence-based management of patients with PAH.
This activity is intended cardiologists, the clinicians responsible for the management of patients with PAH.
The proposed initiative is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.
At the conclusion of an activity, participants should be able to:
- Use evidence-based recommendations to diagnose pulmonary arterial hypertension (PAH)
- Develop evidence-based individualized treatment strategies for patients with PAH
- Implement strategies to incorporate the patient’s perspective into individualized management plans for PAH
Bradley A. Maron, MD
Associate Professor of Medicine
Harvard Medical School
Associate Physician, Division of Cardiovascular Medicine
Medical Director, Cardiopulmonary Exercise Laboratory
Brigham and Women’s Hospital
Co-Director, Pulmonary Vascular Disease Center
Boston VA Healthcare System
Bradley A. Maron, MD is an Associate Professor of Medicine at Harvard Medical School, an Associate Physician in the Division of Cardiovascular Medicine at Brigham and Women’s Hospital, and Co-director of the Pulmonary Vascular Disease Center at the Boston VA Healthcare System. His epidemiological work has aided in clarifying the spectrum of clinical risk related to cardiopulmonary hemodynamics in pulmonary hypertension. His laboratory focus involves utilizing network and systems methodologies to characterize the pathobiological mechanisms underpinning pulmonary vascular disease.
As part of collaborative projects, his group developed a novel risk-assessment code for patients with exercise intolerance that was based on a network analysis of patient-level clinical data. Dr. Maron has co-authored numerous scientific manuscripts and is the lead Editor of a textbook on pulmonary vascular disease. His work has been funded by the National Institutes of Health, American Heart Association, Cardiovascular Medical Research and Education Foundation, Scleroderma Foundation, and the McKenzie Family Trust Foundation. He is the recipient of the distinguished Eleanor and Miles Shore Scholar in Medicine and the Harvard Medical School Excellence in Teaching Award.
John J. Ryan, MD, MRCPI, FACC, FAHA
Director, Dyspnea and Pulmonary Hypertension Centers
Director, Cardiovascular Medicine Unit
University of Utah
Salt Lake City. UT
John J. Ryan, MD, MRCPI, FACC, FAHA is a cardiologist at the University of Utah with extensive training and experience in research investigation and clinical patient care. He is an internationally renowned specialist in pulmonary hypertension and is board-certified in internal medicine, cardiovascular medicine, advanced heart failure and transplant cardiology, and echocardiography and nuclear cardiology. Dr. Ryan is the Director of the University of Utah Pulmonary Hypertension Center and is also Sports Cardiology Consultant for the United States Olympic Committee, the National Basketball Association, the Utah Jazz, and the University of Utah Utes. He is also the Director of Cardiology Curriculum for the University of Utah School of Medicine.
The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The faculty, authors and content developers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Bradley A. Maron, MD: Consultant/Independent Contractor: Actelion
John J. Ryan, MD, MRCPI, FACC, FAHA: Consultant/Independent Contractor: Vertex; Honoraria: Bayer, Janssen Pharma
Planners and Managers
The planners and mangers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Terry Ann Glauser, MD, MPH: Nothing to disclose
The content reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Katie Propst, PhD: Nothing to disclose
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN DESIGNATION STATEMENT
The Potomac Center for Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding CME/MOC credit or the evaluation, please email [email protected].
ABIM MOC RECOGNITION STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME's ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
MOC APPROVAL STATEMENT
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, Improving Rheumatoid Arthritis Care: Understanding the Latest Approvals and Treatment Strategies has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:
MOC Part II CME Activity
- 1.00 MOC
- 1.00 AMA PRA Category 1 Credit™
This course is offered through Rockpointe.
To take this course you will be redirected to Rockpointe's website. You must login or create an account with Rockpointe in order to complete this activity.
Mocingbird works to provide curated, high quality content to our users. Have a suggestion? Want to partner with us? Get in touch!